Data from Pharmawand - Curated by Toby Galbraith - Date added 25 July 2013

An advisory panel to the FDA voted against approving Humira ( (adalimumab) from AbbVie, for treating an inflammatory disease of the spine. The panel of independent advisors called for additional trials to prove the efficacy of the drug in treating early-stages of Spondyloarthritis.

The FDA will take the panel's 12 to 1 vote into consideration while deciding upon the final approval for this new use for the drug.


You will need to login, to leave a comment. is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

Visit Prostate Cancer

Related Content